FcRn Inhibition As a Therapeutic Class

Originally published by our sister publication Specialty Pharmacy ContinuumAmy E. Clarke, DNP, RN, IgCN®Chief Clinical OfficerImmunoglobulin National SocietyCalabasas, CaliforniaLuba Sobolevsky, PharmD, IgCP®President and CEOImmunoglobulin National SocietyCalabasas, CaliforniaThe treatment landscape for immunoglobulin G (IgG)-mediated autoimmune disease is undergoing a significant shift toward mechanism-driven therapeutics. Management has relied on broad immunosuppression, including cort